AstraZeneca Pharma India Limited Business Intelligence Report
AstraZeneca Pharma India Limited Business Intelligence Report
Quality Scores
Latest Quarterly Earnings Summary
Loading latest quarter…
AI Summary
AstraZeneca Pharma India Limited (AZPIL) exhibits the characteristics of a high-quality pharmaceutical entity driven by its parent company’s global R&D pipeline. The business has undergone a significant transformation from a loss-making entity in FY15 to a highly profitable organization with a sales CAGR of 15% over 10 years, accelerating to 31% over the last three years. The business model is increasingly tilted toward high-margin segments like Oncology and CVRM, which has structurally improved the return profile. With a ROCE consistently near 30% and zero long-term debt, the financial…
Key Changes in FY2026
The business has undergone a significant transformation from a legacy pharmaceutical player to an innovation-led leader in chronic disease segments. Over the last decade, AZPIL has pivoted its portfolio toward high-growth areas including Cardiovascular, Renal, Metabolism (CVRM), and Oncology. The recent approval for Enhertu for breast cancer indications highlights a steady move toward biologics and complex specialty medicines. Strategic shift is evident in the margin expansion seen from FY2015 (negative margins) to the current stable double-digit OPMs. The company is successfully leveraging the global parent's pipeline to introduce 'First-in-Class' and 'Best-in-Class' therapies in India. This evolution reflects a transition from a general medicine focus to a specialized,…
Management Commentary
Management execution has been consistent, successfully pivoting the company towards high-growth specialty segments like Oncology. There is high transparency in disclosures, evidenced by the regular conduction of AGMs and detailed corporate presentations. The alignment with AstraZeneca PLC (UK) ensures access to a global best-in-class product portfolio and clinical research. The leadership has successfully navigated the complex Indian regulatory environment while maintaining a 75% promoter holding. However, the recent demand notices from the NPPA regarding overcharging for Symbicort and Betaloc suggest an ongoing struggle with price control regulations. Overall, management has demonstrated a clear ability to drive profitable growth in a competitive landscape.
Financial Highlights
The financial trajectory demonstrates a significant turnaround from an operating loss of INR 11 Cr in FY15 to an operating profit of INR 262 Cr in FY26. Revenue growth has been robust, particularly in the last 24 months, driven by volume growth in the core portfolio. EBITDA margins have stabilized in the 12-16% range, showing resilience despite rising expenses associated with product launches. The company maintains a high-quality balance sheet with negative net debt and a very high current ratio. ROE has stabilized at an impressive 23%, reflecting efficient utilization of shareholder funds. The recent surge in sales to INR 2,276 Cr in FY26 suggests the business is successfully scaling its specialty presence in the Indian market.
Major Opportunities
- MNC parentage with AstraZeneca UK plc (75%)
- Asset-light business model with high ROCE
- Strong 10-year PAT CAGR of 43%
Major Risks
- High regulatory risk from NPPA overcharging notices
- Significant working capital stretch in FY26
- Sharp rise in Inventory Days to 272
About AstraZeneca Pharma India Limited's Annual Report & Financial Performance
The latest AstraZeneca Pharma India Limited annual report (FY2026) is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis, audited financial statements, the director's report, the corporate governance and auditor's reports, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This Business Intelligence Hub consolidates the official filings with AI-generated financial analysis so investors can see how revenue, operating margin, cash flow quality, capex, dividends, net debt and management outlook have changed — without reading the entire filing.
What this AstraZeneca Pharma India Limited research covers
- Fundamental & business analysis
- Financial statements & performance
- Management commentary & discussion
- Corporate governance & auditor report
- Cash flow analysis & capital allocation
- Valuation analysis & business quality
- Growth analysis & competitive position
- Risk, SWOT & moat analysis
- Quarterly earnings & conference-call summary
- Sector, industry & peer comparison
- Latest official company filings
- Business outlook & long-term growth
AstraZeneca Pharma India Limited — Frequently Asked Questions
Explore more AstraZeneca Pharma India Limited research
AI Top Insights — Premium
Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.